Subtype
Liver Carcinoma
CI-CAN-00001073Explore in graph →
783 active trials14 approved drugs17 evidence items
- NCIt
- C7927
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001073Explore in graph →
Clinical trials
3,370 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (387)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02921139 | Comparing Re-TACE Versus SABR for Post-prior-TACE Incompletely Regressed HCC: a Randomized Controlled Trial (TASABR)(TASABR) | unknown | N/A | 120 | Dalin Tzu Chi General HospitalOTHER | 1 | Aug 30, 2021 | clinicaltrials |
| NCT05009550 | ESP Block on Patient Outcomes in Patients With Liver Tumor Undergoing Radiofrequency Ablation | unknown | N/A | 30 | TC Erciyes UniversityOTHER | 1 | Aug 17, 2021 |
| NCT05007587 | Lenvatinib Plus HAIC of Modified FOLFOX Regime vs Lenvatinib Plus HAIC of ROX Regime in Patients With Advanced HCC | unknown | Early Phase 1 | 60 | Zhejiang Cancer HospitalOTHER | 1 | Aug 16, 2021 | clinicaltrials |
| NCT04994236 | Hepatic Artery Infusion Chemotherapy for Unresectable Hepatocelluar Carcinoma Who Failed to Systemic Therapy | unknown | Phase 2 | 49 | Hui-Chuan SunOTHER | 1 | Aug 13, 2021 | clinicaltrials |
| NCT04996446 | ALPPS Combined With Tislelizumab in Liver Malignancy | unknown | Phase 2 | 20 | Fudan UniversityOTHER | 1 | Aug 9, 2021 | clinicaltrials |
| NCT04996459 | Tislelizumab in the Systematic Treatment of Advanced Hepatocellular Carcinoma | unknown | — | 40 | Fudan UniversityOTHER | 1 | Aug 9, 2021 | clinicaltrials |
| NCT04639284 | Anti-angiogenic Agents Plus Anti-PD-1 Antibodies for uHCC | unknown | — | 200 | Shanghai Zhongshan HospitalOTHER | 1 | Jul 26, 2021 | clinicaltrials |
| NCT04127396 | Lenvatinib Plus TACE Versus Sorafenib Plus TACE for HCC With PVTT | unknown | Phase 4 | 72 | Beijing Ditan HospitalOTHER | 1 | Jul 23, 2021 | clinicaltrials |
| NCT04920214 | Application Value of CEUS Li-RADS in Hepatic Focal Lesions in Patients With Non-high Risk Factors for HCC | unknown | — | 500 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Jul 15, 2021 | clinicaltrials |
| NCT04961138 | Pre-operative Neoadjuvant Therapy Combined With Surgery for Treating Stage III Hepatocellular Carcinoma | unknown | N/A | 164 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 0 | Jul 14, 2021 | clinicaltrials |
| NCT04961788 | Anti-PD1 Antibody Toripalimab Combined With Gemox as First-line Therapy in Late-stage Intrahepatic Cholangiocarcinoma | unknown | Phase 2 | 30 | Shanghai Zhongshan HospitalOTHER | 1 | Jul 14, 2021 | clinicaltrials |
| NCT04961918 | The Efficacy of Hepatic Arterial Infusion Chemotherapy (HAIC) Combine Lenvatinib and Durvalumab (HILL) in Advanced Hepatocellular Carcinoma (HCC) | unknown | Phase 2 | 36 | Sun Yat-sen UniversityOTHER | 1 | Jul 14, 2021 | clinicaltrials |
| NCT04961970 | HAIC With FOLFOX Versus Systemic Chemotherapy With GP for Unresectable ICC | unknown | Phase 3 | 188 | Shi MingOTHER | 1 | Jul 14, 2021 | clinicaltrials |
| NCT04955119 | Fusion Imaging Contrast-enhanced Ultrasound LI-RADS | unknown | N/A | 132 | Tianjin Third Central HospitalOTHER | 1 | Jul 8, 2021 | clinicaltrials |
| NCT03951597 | Combined Therapy Using Oxaliplatin and Gemcitabine Chemotherapy, Lenvatinib and PD1 Antibody (JS001) for Patients With Advanced and Unresectable Intrahepatic Cholangiocarcinoma | unknown | Phase 2 | 30 | Shanghai Zhongshan HospitalOTHER | 1 | Jul 7, 2021 | clinicaltrials |
| NCT04951141 | Clinical Study of Intratumoral Injection of CAR-T Cells in the Treatment of Advanced Liver Tumors | unknown | Early Phase 1 | 10 | Beijing Immunochina Medical Science & Technology Co., Ltd.INDUSTRY | 1 | Jul 6, 2021 | clinicaltrials |
| NCT04947956 | Camrelizumab in Patients With Unresectable Hepatocellular Carcinoma | unknown | — | 1,000 | Shanghai Zhongshan HospitalOTHER | 0 | Jul 1, 2021 | clinicaltrials |
| NCT04806243 | Carelizumab Combined With Regorafenib in the Treatment of HCC（CARE-2020） | unknown | Phase 2 | 69 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Jun 30, 2021 | clinicaltrials |
| NCT04331743 | A Study to Evaluate the Safety and Efficacy of PLM60 in Advanced HCC | unknown | Phase 1 | 18 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 0 | Jun 16, 2021 | clinicaltrials |
| NCT04926532 | Toripalimab Plus Sorafenib in Patients With Advanced-Stage Hepatocellular Carcinoma(Toripalimab) | unknown | Phase 1 / Phase 2 | 30 | Shanghai Zhongshan HospitalOTHER | 1 | Jun 15, 2021 | clinicaltrials |
| NCT04913480 | SBRT and Durvalumab for Inoperable/Unresectable Hepatocellular Carcinoma | unknown | Phase 2 | 37 | The University of Hong KongOTHER | 1 | Jun 4, 2021 | clinicaltrials |
| NCT04909866 | The Efficacy and Safety of TACE, Lenvatinib and Camrelizumab in the Treatment of BCLC Stage B/C Hepatocellular Carcinoma: a Single-arm, Single-center, Open-label Study | unknown | Phase 2 / Phase 3 | 40 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jun 2, 2021 | clinicaltrials |
| NCT02964260 | RCT of TAE Simultaneously Combined Thermal Ablation for Large Hepatocellular Carcinoma | unknown | N/A | 410 | Sun Yat-sen UniversityOTHER | 1 | May 14, 2021 | clinicaltrials |
| NCT04517227 | The Combination Therapy of TACE and Ablation With Durvalumab in Hepatocellular Carcinoma at Intermediate Stage (TAD) | unknown | N/A | 30 | Fudan UniversityOTHER | 0 | May 3, 2021 | clinicaltrials |
| NCT02556619 | Randomized Control Trial (RCT) of Early Palliative Care for HCC | unknown | N/A | 72 | The University of Texas Health Science Center, HoustonOTHER | 1 | Apr 27, 2021 | clinicaltrials |
| NCT04814030 | Transarterial Infusion of PD-1 Antibody Plus TACE-HAIC for Unresectable HCC: a Single-arm, Phase 2 Clinical Trial(AIPD-1) | unknown | Phase 2 | 80 | Sun Yat-sen UniversityOTHER | 1 | Apr 23, 2021 | clinicaltrials |
| NCT03342677 | Evaluation of Gd-EOB-DTPA MRI for Detection and Characterization of Liver Nodules in Cirrhotic Patients Undergoing Liver Transplantation and Potential Impact on Transplant Eligibility | unknown | N/A | 80 | University Health Network, TorontoOTHER | 1 | Apr 19, 2021 | clinicaltrials |
| NCT03971201 | A Randomized Phase II Trial of Surgery Plus Sorafenib vs. Sorafenib Alone for Hepatocellular Cancer (HCC) With Portal Vein Invasion | unknown | Phase 2 | 200 | White Plains HospitalOTHER | 1 | Apr 14, 2021 | clinicaltrials |
| NCT04843943 | Sintilimab Combined With Bevacizumab Biosimilar for Potentially Resectable Intermediate HCC | unknown | Phase 1 / Phase 2 | 30 | Fudan UniversityOTHER | 0 | Apr 14, 2021 | clinicaltrials |
| NCT04834986 | Tislelizumab Combined With Lenvatinib for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma | unknown | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Apr 8, 2021 | clinicaltrials |
| NCT04826406 | A Study of Camrelizumab Combined Apatinib in Hepatocellular Carcinoma Previously Treated With Immune Checkpoint Inhibitors (ICIs). | unknown | Phase 2 | 40 | Hunan Cancer HospitalOTHER | 1 | Apr 1, 2021 | clinicaltrials |
| NCT04167293 | Combination of Sintilimab and Stereotactic Body Radiotherapy in Hepatocellular Carcinoma (ISBRT01)(ISBRT01) | unknown | Phase 2 / Phase 3 | 116 | Mian XIOTHER | 1 | Mar 23, 2021 | clinicaltrials |
| NCT02806076 | RFA for Small HCC With No-touch Technique and Dual Cooled-Wet Electrode | unknown | N/A | 100 | Seoul National University HospitalOTHER | 1 | Mar 19, 2021 | clinicaltrials |
| NCT04803019 | Transarterial Embolization Alone Versus Drug-Eluting Beads Chemoembolization for Hepatocellular Carcinoma(RAD-18-TAcE) | unknown | Phase 3 | 154 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Mar 19, 2021 | clinicaltrials |
| NCT02854241 | Comparison of Biannual Ultrasonography and Annual Unenhanced Magnetic Resonance Imaging for HCC Surveillance | unknown | N/A | 40 | Seoul National University HospitalOTHER | 1 | Mar 17, 2021 | clinicaltrials |
| NCT03742453 | Evaluation of Diagnostic Accuracy of CEUS for HCC Diagnosis | unknown | N/A | 117 | Seoul National University HospitalOTHER | 1 | Mar 17, 2021 | clinicaltrials |
| NCT04331184 | RFA Using Combined Bipolar and Monopolar Energy Deliver With Twin Cooled-Wet Electrodes | unknown | N/A | 102 | Seoul National University HospitalOTHER | 1 | Mar 17, 2021 | clinicaltrials |
| NCT04471272 | RFA Using Gradual RF Energy Delivery Mode With Octopus Electrodes | unknown | N/A | 120 | Seoul National University HospitalOTHER | 1 | Mar 17, 2021 | clinicaltrials |
| NCT04665609 | Thermal Ablation Combined With Anlotinib and TQB2450 Solution for HCC | unknown | Phase 3 | 80 | Chinese PLA General HospitalOTHER | 1 | Mar 4, 2021 | clinicaltrials |
| NCT04121273 | GPC3-targeted CAR-T Cell for Treating GPC3 Positive Advanced HCC | unknown | Phase 1 | 20 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Mar 3, 2021 | clinicaltrials |
| NCT04042805 | Sintilimab Combined With Lenvatinib in Local Advanced Hepatocellular Carcinoma | unknown | Phase 2 | 36 | Baocai XingOTHER | 1 | Mar 2, 2021 | clinicaltrials |
| NCT02786342 | Italian Study Of Validation Of Angiogenesis Polymorphisms In HCC Patients Treated With Sorafenib(INNOVATE) | unknown | — | 160 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | Feb 26, 2021 | clinicaltrials |
| NCT04773769 | Study of Guanábana Leaves for The Treatment of Patients With Gastric, Gastroesophageal Junction, Pancreatic and Colorectal Adenocarcinomas; Hepatocellular Carcinoma, and Low Grade Lymphomas | unknown | N/A | 54 | Auxilio Mutuo Cancer CenterOTHER | 1 | Feb 26, 2021 | clinicaltrials |
| NCT04170179 | Systemic Chemotherapy Plus Lenvatinib and Toripalimab for HCC With Extrahepatic Metastasis | unknown | Phase 2 | 25 | Sun Yat-sen UniversityOTHER | 1 | Feb 23, 2021 | clinicaltrials |
| NCT04229355 | DEB-TACE Plus Lenvatinib or Sorafenib or PD-1 Inhibitor for Unresectable Hepatocellular Carcinoma | unknown | Phase 3 | 90 | Guangxi Medical UniversityOTHER | 1 | Feb 9, 2021 | clinicaltrials |
| NCT04741165 | Study of HX008 in Combination With Bevacizumab or Lenvatinib for the Treatment of Advanced Hepatocellular Carcinoma (HCC) | unknown | Phase 2 | 72 | Taizhou Hanzhong biomedical co. LTDINDUSTRY | 1 | Feb 5, 2021 | clinicaltrials |
| NCT03941626 | Autologous CAR-T/TCR-T Cell Immunotherapy for Solid Malignancies | unknown | Phase 1 / Phase 2 | 50 | Shenzhen BinDeBio Ltd.INDUSTRY | 1 | Feb 4, 2021 | clinicaltrials |
| NCT04738188 | Efficacy and Safety of TACE on Downstaging Hepatocellular Carcinoma Beyond UCSF Criteria; | unknown | N/A | 226 | Beijing Tsinghua Chang Gung HospitalOTHER | 1 | Feb 4, 2021 | clinicaltrials |
| NCT04730388 | ATEZOLIZUMAB - BEVACIZUMAB in the Treatment Hepatocellular Carcinoma Inoperable or(HEPATOFIT) | unknown | — | 100 | University Hospital, BrestOTHER | 0 | Jan 29, 2021 | clinicaltrials |
| NCT03794440 | A Study to Evaluate the Efficacy and Safety of Sintilimab in Combination With IBI305 (Anti-VEGF Monoclonal Antibody) Compared to Sorafenib as the First-Line Treatment for Advanced Hepatocellular Carcinoma. | unknown | Phase 2 / Phase 3 | 595 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Jan 22, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Aug 30, 2021source: clinicaltrials